Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. FFAI
6. FFR
7. AZN
8. FICO
9. GMAB
10. CART

Go back to Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

Galectin Therapeutics (GALT) Will Present Preclinical GR-MD-02 Data at SITC Annual Meeting

November 11, 2015 8:10 AM EST

Galectin Therapeutics (NASDAQ: GALT) announces that preclinical research from a study led by Stefanie Linch, Ph.D. in the laboratory of tumor immunology expert William L. Redmond, Ph.D. of the Providence Cancer Center's Earle A. Chiles Research Institute was presented at the Society for Immunotherapy of Cancer's (SITC) 30th Anniversary Annual Meeting. The meeting was held November 4-8 in National Harbor, Maryland. The studies presented were conducted by the Institute in collaboration with Galectin Therapeutics.

The poster presentation is titled "Galectin-3 inhibition... More